PMV Pharma reports Q2 cash of $148.3mln, expected runway to 2026.

• PMV Pharma to review Phase 2 PYNNACLE trial interim analysis on Sept 10 • Interim analysis includes data for approximately 65 patients • 18 weeks of follow-up data to be included • $148.3M in cash, cash equivalents, and marketable securities as of June 30, 2025 • Cash runway expected to end of 2026

PMV Pharmaceuticals (NASDAQ: PMVP), a precision oncology company, has announced its plans to review interim analysis data from the Phase 2 PYNNACLE clinical trial on September 10, 2025. The interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up, with about 45% of these patients being from the ovarian cancer cohort. The company ended the second quarter of 2025 with $148.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway through the end of 2026.

The Phase 2 PYNNACLE trial is evaluating rezatapopt, a first-in-class, small molecule p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The interim analysis will provide meaningful insights into rezatapopt's efficacy profile, particularly in the ovarian cancer cohort.

PMV Pharmaceuticals reported a net loss of $21.2 million for the second quarter of 2025, compared to $1.2 million in the same period last year. This increase is largely explained by a one-time tax benefit in 2024 from the sale of New Jersey accumulated net operating losses. Excluding this non-recurring item, the operational loss increased by approximately $3.8 million, aligning with the company's expanded clinical activities.

The company's R&D expenses increased to $18.4 million year-over-year, primarily due to the advancement of the rezatapopt program. Meanwhile, G&A expenses decreased to $4.5 million, demonstrating prudent cost management in non-research areas.

PMV Pharmaceuticals is headquartered in Princeton, New Jersey, and is pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company's co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. PMV Pharma combines unique biological understanding with a pharmaceutical development focus.

References:
[1] https://www.stocktitan.net/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2025-financial-results-wdxz8k0tux45.html
[2] https://www.globenewswire.com/news-release/2025/08/07/3129289/0/en/PMV-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Corporate-Highlights.html